{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:58Z","timestamp":1784977258404,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04221-y","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:00:30Z","timestamp":1770199230000},"page":"3103-3112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Compatibility of different PET\/CT criteria in evaluating treatment response and survival in non-small cell lung cancer patients treated with immunotherapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-4141","authenticated-orcid":false,"given":"\u0130mdat","family":"Ero\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011furay","family":"Aydos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin \u00dcnl\u00fcer","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selahattin Bar\u0131\u015f","family":"K\u00fc\u00e7\u00fckali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytu\u011f","family":"\u00dcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"G\u00fcrler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"3","key":"4221_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"4221_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"issue":"1","key":"4221_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01243894-200601000-00014","volume":"1","author":"JF Vansteenkiste","year":"2006","unstructured":"Vansteenkiste JF, Stroobants SS. PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol. 2006;1(1):71\u20133.","journal-title":"J Thorac Oncol"},{"key":"4221_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030878","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, et al. ITA-IMMUNO-PET: the role of [18F]FDG PET\/CT for assessing response to immunotherapy in patients with some solid tumors. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030878.","journal-title":"Cancers (Basel)"},{"key":"4221_CR5","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618.","journal-title":"Front Immunol"},{"issue":"25","key":"4221_CR6","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO-24-01324","volume":"42","author":"ME Daly","year":"2024","unstructured":"Daly ME, Singh N, Ismaila N. Management of stage III non-small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2024;42(25):3058\u201360.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4221_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u201376.","journal-title":"Ann Oncol"},{"issue":"7","key":"4221_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1148\/rg.317115050","volume":"31","author":"H Chalian","year":"2011","unstructured":"Chalian H, T\u00f6re HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST versions 1.1 and 1.0. Radiographics. 2011;31(7):2093\u2013105.","journal-title":"Radiographics"},{"issue":"12","key":"4221_CR9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/0959-8049(95)00421-1","volume":"31a","author":"P Price","year":"1995","unstructured":"Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET oncology concerted action and the EORTC PET study group. Eur J Cancer. 1995;31a(12):1924\u20137.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"4221_CR10","doi-asserted-by":"publisher","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","volume":"50 Suppl 1","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122s\u201350s.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"4221_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","volume":"44","author":"K Pinker","year":"2017","unstructured":"Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):55\u201366.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4221_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"4221_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370.","journal-title":"Nat Immunol"},{"issue":"4","key":"4221_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","volume":"42","author":"D Pardoll","year":"2015","unstructured":"Pardoll D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015;42(4):523\u201338.","journal-title":"Semin Oncol"},{"issue":"3","key":"4221_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385\u201396.","journal-title":"Ann Oncol"},{"issue":"3","key":"4221_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Sch\u00f6der H, Humm JL, Ni A, Michaud L, et al. (18)F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335\u201341.","journal-title":"J Nucl Med"},{"issue":"9","key":"4221_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58(9):1421\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"4221_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4221_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276\u201382.","journal-title":"Biochem Med (Zagreb)"},{"issue":"Pt 3","key":"4221_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","volume":"86","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Y, Ren Y, Zhang Q, Yi P, Cheng C. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin Cancer Biol. 2022;86(Pt 3):542\u201365.","journal-title":"Semin Cancer Biol"},{"issue":"23","key":"4221_CR21","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4221_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/fon.15.28","volume":"11","author":"A Dimitrakopoulou-Strauss","year":"2015","unstructured":"Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncol. 2015;11(7):1083\u201391.","journal-title":"Future Oncol"},{"issue":"12","key":"4221_CR23","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1007\/s00259-024-06794-8","volume":"51","author":"M Masse","year":"2024","unstructured":"Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, et al. [(18)F]FDG-PET\/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal. Eur J Nucl Med Mol Imaging. 2024;51(12):3696\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"4221_CR24","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00259-023-06243-y","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. The prognostic value of [18F] FDG PET\/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria. Eur J Nucl Med Mol Imaging. 2023;50(9):2699\u2013714.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4221_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40336-022-00522-8","volume":"10","author":"H Saadani","year":"2022","unstructured":"Saadani H, Aalbersberg EA, Schats W, Hoekstra OS, Stokkel MP, de Vet HC. Comparing [18F] FDG PET\/CT response criteria in melanoma and lung cancer patients treated with immunotherapy: a systematic review. Clin Transl Imaging. 2022;10(6):643\u201361.","journal-title":"Clin Transl Imaging"},{"issue":"3","key":"4221_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/RLU.0000000000002921","volume":"45","author":"A Annovazzi","year":"2020","unstructured":"Annovazzi A, Vari S, Giannarelli D, Pasqualoni R, Sciuto R, Carpano S, et al. Comparison of 18F-FDG PET\/CT criteria for the prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors. Clin Nucl Med. 2020;45(3):187\u201394.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"4221_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42(3):386\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"4221_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/pcmr.12503","volume":"29","author":"BY Kong","year":"2016","unstructured":"Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29(5):572\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"13","key":"4221_CR29","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s00259-017-3802-5","volume":"44","author":"S Rossi","year":"2017","unstructured":"Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017;44(13):2310\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4221_CR30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fonc.2020.01090","volume":"10","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Toschi L, Lopci E. Comparison of metabolic and morphological response criteria for early prediction of response and survival in NSCLC patients treated with anti-PD-1\/PD-L1. Front Oncol. 2020;10:1090.","journal-title":"Front Oncol"},{"key":"4221_CR31","doi-asserted-by":"crossref","unstructured":"Comito F, Pagani R, Aprile M, Dragonetti V, Bonazzi N, Battisti G, et al. Comparison of PET-based criteria of evaluation of response to immunotherapy in patients with advanced melanoma. Am Soc Clin Oncol. 2022;e21536.","DOI":"10.1200\/JCO.2022.40.16_suppl.e21536"},{"key":"4221_CR32","unstructured":"Sosyal G\u00fcvenlik Kurumu Sa\u011flik Uygulama Tebli\u011fi [Available from: https:\/\/mevzuat.gov.tr\/mevzuat?MevzuatNo=17229&MevzuatTur=9&MevzuatTertip=5."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04221-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04221-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04221-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:13Z","timestamp":1784975353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04221-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4221"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04221-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study. All data were anonymized and handled in accordance with institutional and ethical guidelines.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}